Vaishalee P. Kenkre, MD close
Vaishalee P. Kenkre, MD

New Patients

Contact the Welcome Center for help choosing a new primary care doctor.

For Referring Physicians

How to refer a patient

Vaishalee P. Kenkre, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Kenkre is an assistant professor of medicine within the division of hematology/oncology at the UW School of Medicine and Public Health and at the William S. Middleton Memorial Veterans Hospital. She completed her medical degree at the University of Michigan Medical School in Ann Arbor, Michigan, and her postgraduate internship/residency training in Internal Medicine at the Tufts-New England Medical Center, in Boston, Massachusetts. Most recently, she completed her fellowship in Hematology/Oncology at the University of Chicago in Chicago, Illinois, in 2010.


Dr. Kenkre’s clinical interests are in hematology, specifically lymphoma and bone marrow transplantation. Her professional organization memberships include the American Society of Hematology, the American Society of Clinical Oncology and the American Medical Association.



Bone Marrow Transplant (BMT)

CAR T-cell Therapy (Adult)

Hematology (Leukemia, Lymphoma and Multiple Myeloma)

Hematology (non cancer)

Leukemia, Lymphoma, Multiple Myeloma


UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Hematology
Medical Oncology
Fellowship University of Chicago Medical Center, Chicago, IL
Residency Tufts-New England Medical Center, Boston, MA
Internship Tufts-New England Medical Center, Boston, MA
Medical School University of Michigan Medical School, Ann Arbor, MI

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

Dr. Kenkre is part of the Lymphoma Disease Oriented Work Group, which focuses on improving therapeutic options for patients with lymphoma. She is interested in drug development and novel therapeutics for patients with lymphoma and improving outcomes for those patients undergoing bone marrow transplantation.

PubMed Articles
Erbe AK Wang W Carmichael L Hoefges A Grzywacz B Reville PK Ranheim EA Hank JA Kim K Seo S Mendonca EA Song Y Kenkre VP Hong F Gascoyne RD Paietta E Horning SJ Miller JS Kahl B Sondel PM Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab. J Immunother Cancer . 2019 Mar 12;7(1):70
[PubMed ID: 30871628]
Sahasrabudhe K Otto M Hematti P Kenkre V TCR αβ+/CD19+ cell depletion in haploidentical hematopoietic allogeneic stem cell transplantation: a review of current data. Leuk Lymphoma . 2019 Mar;60(3):598-609
[PubMed ID: 30187806]
Shah NN Szabo A Saba R Strelec L Kodali D Vaughn JL Esan O Yang DT Mato AR Kanate AS Olteanu H Hamadani M Fenske TS Kenkre VP Svoboda J Cashen AF Epperla N Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. Clin Lymphoma Myeloma Leuk . 2019 Feb;19(2):95-102
[PubMed ID: 30581160]
Smith SM Godfrey J Ahn KW DiGilio A Ahmed S Agrawal V Bachanova V Bacher U Bashey A Bolaños-Meade J Cairo M Chen A Chhabra S Copelan E Dahi PB Aljurf M Farooq U Ganguly S Hertzberg M Holmberg L Inwards D Kanate AS Karmali R Kenkre VP Kharfan-Dabaja MA Klein A Lazarus HM Mei M Mussetti A Nishihori T Ramakrishnan Geethakumari P Saad A Savani BN Schouten HC Shah N Urbano-Ispizua A Vij R Vose J Sureda A Hamadani M Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Cancer . 2018 Jun 15;124(12):2541-2551
[PubMed ID: 29645093]
Casulo C Friedberg JW Ahn KW Flowers C DiGilio A Smith SM Ahmed S Inwards D Aljurf M Chen AI Choe H Cohen J Copelan E Farooq U Fenske TS Freytes C Gaballa S Ganguly S Jethava Y Kamble RT Kenkre VP Lazarus H Lazaryan A Olsson RF Rezvani AR Rizzieri D Seo S Shah GL Shah N Solh M Sureda A William B Cumpston A Zelenetz AD Link BK Hamadani M Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant . 2018 Jun;24(6):1163-1171
[PubMed ID: 29242111]
Shah NN Ahn KW Litovich C Fenske TS Ahmed S Battiwalla M Bejanyan N Dahi PB Bolaños-Meade J Chen AI Ciurea SO Bachanova V DeFilipp Z Epperla N Farhadfar N Herrera AF Haverkos BM Holmberg L Hossain NM Kharfan-Dabaja MA Kenkre VP Lazarus HM Murthy HS Nishihori T Rezvani AR D'Souza A Savani BN Ulrickson ML Waller EK Sureda A Smith SM Hamadani M Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. Blood Adv . 2018 Apr 24;2(8):933-940
[PubMed ID: 29685953]
Epperla N Ahn KW Armand P Jaglowski S Ahmed S Kenkre VP Savani B Jagasia M Shah NN Fenske TS Sureda A Smith SM Hamadani M Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. Biol Blood Marrow Transplant . 2018 Jan;24(1):78-85
[PubMed ID: 29032272]
Epperla N Hamadani M Cashen AF Ahn KW Oak E Kanate AS Calzada O Cohen JB Farmer L Ghosh N Tallarico M Nabhan C Costa LJ Kenkre VP Hari PN Fenske TS Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. Hematol Oncol . 2017 Dec;35(4):528-535
[PubMed ID: 28066928]
Kenkre VP Hong F Cerhan JR Lewis M Sullivan L Williams ME Gascoyne RD Horning SJ Kahl BS Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma. Clin Cancer Res . 2016 Feb 15;22(4):821-6
[PubMed ID: 26510856]
Wilson WH Young RM Schmitz R Yang Y Pittaluga S Wright G Lih CJ Williams PM Shaffer AL Gerecitano J de Vos S Goy A Kenkre VP Barr PM Blum KA Shustov A Advani R Fowler NH Vose JM Elstrom RL Habermann TM Barrientos JC McGreivy J Fardis M Chang BY Clow F Munneke B Moussa D Beaupre DM Staudt LM Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med . 2015 Aug;21(8):922-6
[PubMed ID: 26193343]
Kenkre VP Kahl BS What is the best initial therapy for a patient with symptomatic low-grade follicular lymphoma? Cancer J . 2012 Sep-Oct;18(5):383-9
[PubMed ID: 23006941]
Kenkre VP Kahl BS The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways. Curr Hematol Malig Rep . 2012 Sep;7(3):216-20
[PubMed ID: 22688757]
Kenkre VP Kahl B Nodal marginal zone lymphoma: what do we really know? Oncology (Williston Park) . 2012 Jan;26(1):108-9
[PubMed ID: 22393804]
Kenkre VP Long WL Eickhoff JC Blank JH McFarland TA Bottner W Rezazedeh H Werndli JE Bailey HH Kahl BS Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. Leuk Lymphoma . 2011 Sep;52(9):1675-80
[PubMed ID: 21864042]
Kenkre VP Kahl BS Follicular lymphoma: emerging therapeutic strategies. Expert Rev Hematol . 2010 Aug;3(4):485-95
[PubMed ID: 21083037]